Publication

Article

CURE

Winter 2010
Volume9
Issue 4

Online Tool Helps Childhood Cancer Survivors Monitor Late Effects

Online tool helps cancer survivors know what to look for years after treatment

The increase of five-year survival rates of childhood cancers to 80 percent signifies a need for research and awareness of late effects of cancer and its treatment. Late effects, such as heart failure or secondary cancers, can occur years after a person finishes treatment and affect more than two-thirds of childhood cancer survivors.

The National Children’s Cancer Society offers an interactive survey, the Late Effects Assessment Tool, for pediatric cancer survivors of any age to assess their risk of various late effects.

The survey takes a few minutes to complete and provides a comprehensive list of possible late effects, although risks vary according to cancer, treatment and individual patient characteristics. Survivors are encouraged to print out the completed report and discuss the possible late effects with their medical team to determine the best strategy for follow-up and screening for specific late effects. The report also includes a directory of clinics that adhere to the Pediatric Oncology Group Resource guidelines for childhood cancer survivors.

The tool, which the NCCS developed with Robert Hayashi, MD, the director of hematology/oncology at the St. Louis Children’s Hospital, requires registration, but all information is private, and users can opt-in to save their information with the site for later use. Information is updated twice a year to include the latest research and approved treatments for various cancers.

Related Videos
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with short brown hair, wearing glasses.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of a man wearing a black suit and tie.
Image of a man with rectangular glasses and a goatee.
Image of a woman with a brown hair tied into a bun.
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Related Content